Combining targeted drug with chemotherapy offers longer life to b-cell cancer patients

Because of the significant benefit found in combining the targeted drug ibrutinib with standard chemotherapy for relapsed chronic lymphocytic leukemia or small lymphocytic lymphoma, an interim analysis has closed the international HELIOS phase III clinical trial.

Read the whole article on Science Daily

More from Science Daily